Excess of severe autoimmune diseases in women with premature ovarian insufficiency: a population-based study.
Level 3 - non-randomized controlled study
Nationwide matched retrospective cohort and case-control study using administrative registries
PubMed 39322013 · doi:10.1093/humrep/deae213
What was done
A nationwide Finnish registry study (1988–2017) evaluated 3,972 women with spontaneous premature ovarian insufficiency (POI, identified via hormone replacement therapy reimbursement) and 15,708 female population controls matched 1:4 by age and municipality. Women with prior cancer or bilateral oophorectomy were excluded. Severe autoimmune conditions treated in specialized care (1970–2017) were tracked through the Hospital Discharge Registry. Binary logistic regression evaluated odds ratios (ORs) for pre-existing autoimmune conditions, and standardized incidence ratios (SIRs) assessed new-onset autoimmune disease in 3-year intervals following POI diagnosis.
What was found
Pre-index severe autoimmune disease was present in 5.6% (n = 233) of women with POI compared to controls (OR 2.6, 95% CI 2.2 to 3.1). Significant pre-index associations included polyglandular autoimmune disease (OR 25.8, 95% CI 9.0 to 74.1), Addison's disease (OR 22.9, 95% CI 7.9 to 66.1), vasculitis (OR 10.2, 95% CI 4.3 to 24.5), systemic lupus erythematosus (OR 6.3, 95% CI 4.2 to 20.3), rheumatoid arthritis (OR 2.3, 95% CI 1.7 to 3.2), sarcoidosis (OR 2.3, 95% CI 1.2 to 4.5), inflammatory bowel disease (OR 2.2, 95% CI 1.5 to 3.3), and hyperthyroidism (OR 1.9, 95% CI 1.2 to 3.1), with no significant differences for type 1 diabetes or ankylosing spondylitis. Post-POI diagnosis, the SIR for incident severe autoimmune disease was 2.8 (95% CI 2.3 to 3.4) in the first 3 years, declining to 1.3 (95% CI 1.1 to 1.6) after 12 years.
Why it matters
This study provides population-scale evidence that spontaneous POI is strongly linked to multiple severe autoimmune disorders both before and after diagnosis. It underscores the shared immunological mechanisms underlying POI and highlights the need for ongoing autoimmune surveillance in these patients.
Limits
The study only captured severe autoimmune disorders managed in specialized inpatient/hospital care, excluding milder conditions managed in primary care and likely underestimating true prevalence. Registry data lacked specific laboratory markers (such as autoantibody titers) and lifestyle or genetic confounders, and surveillance bias around the time of POI diagnosis could account for part of the early post-diagnosis incidence spike.